Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the best small cap stocks to buy for 10x potential.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) announced financial results for fiscal Q1 2026 on May 6, reporting that it reaffirmed U.S
Food and Drug Administration (FDA) alignment on the planned pathway to a Biologics License Application (BLA) submission for TSHA-102. This came after a recent initial breakthrough therapy Type B multidisciplinary meeting with the FDA and includes pivotal trial design and endpoints, and BLA submission scenarios, including the potential to submit for approval based on the six-month interim analysis from the REVEAL pivotal trial. Taysha Gene Therapies, Inc. (NASDAQ:TSHA) also reported that it further advanced dosing in the REVEAL pivotal trial, with multiple patients dosed across several clinical trial sites.
Furthermore, enrollment in the ASPIRE trial is ongoing across several clinical trial sites, and TSHA-102 is continuing to be generally well-tolerated. Taysha Gene Therapies, Inc. (NASDAQ:TSHA) also initiated a BLA-enabling PPQ campaign for TSHA-102 using a commercial manufacturing process in April 2026. Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a clinical-stage biotechnology company that develops and commercializes adeno-associated virus (AAV) based gene therapies to treat monogenic diseases of the central nervous system.